RxDoctor Payments DataLook up a doctor →

Robert Knox, MD

Gastroenterology · Murfreesboro, TNNPI 1457349425

Payments from drug & device makers

$20,380in general payments, 2019–2025

Across 963 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Gilead$1K
  • Johnson & Johnson$1K
  • QOL Medical, LLC$865
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$1,8009%
  • Speaking & faculty fees$4002%
  • Food & beverage$18,03288%
  • Education$1481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,380 in reported general payments places this provider in the 80th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$399,590
Medicare patients
529
Services billed
14,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$545,445
RinvoqUpadacitinib13$99,282
CreonLipase/Protease/Amylase29$54,125
XifaxanRifaximin13$39,358
LinzessLinaclotide37$20,728
Mesalamine16$8,729
Ursodiol20$7,027
Omeprazole374$5,275
Dexlansoprazole DrDexlansoprazole14$4,394
Esomeprazole Magnesium36$4,155
Budesonide EcBudesonide17$3,694
Balsalazide Disodium11$2,787
Pantoprazole Sodium141$1,769
Budesonide DrBudesonide34$1,548
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine36$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,192$545,44521 claims
AbbVieRinvoq, Creon, Linzess$6,302$174,13479 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,859$39,35813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →